These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2539786)

  • 1. [DNA topoisomerases and resistance to anticancer agents].
    Andoh T; Okada K
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):569-75. PubMed ID: 2539786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
    Liu LF; D'Arpa P
    Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
    [No Abstract]   [Full Text] [Related]  

  • 4. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
    Yang CJ; Horton JK; Cowan KH; Schneider E
    Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
    Bendetz-Nezer S; Gazit A; Priel E
    Mol Pharmacol; 2004 Sep; 66(3):627-34. PubMed ID: 15322255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
    Zhao R; al-Said NH; Sternbach DL; Lown JW
    J Med Chem; 1997 Jan; 40(2):216-25. PubMed ID: 9003520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
    Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
    Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
    Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
    Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
    [No Abstract]   [Full Text] [Related]  

  • 19. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
    Muscarella DE; Rachlinski MK; Sotiriadis J; Bloom SE
    Exp Cell Res; 1998 Jan; 238(1):155-67. PubMed ID: 9457068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Topoisomerases: therapeutic value].
    Faure P; Madelaine I
    Ann Pharm Fr; 1996; 54(1):40-4. PubMed ID: 8702194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.